NEW YORK--(BUSINESS WIRE)--Roy Jacobs & Associates a law firm representing investors nationwide, is investigating potential claims on behalf of shareholders of Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company") (NasdaqGS: PCRX) concerning possible breaches of fiduciary duty and securities law violations.
For further information, please contact Roy L. Jacobs, Esq. toll-free at 1-888-884-4490 or by e-mail at email@example.com.
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products primarily for use in hospitals and ambulatory surgery centers worldwide. Its product pipeline includes EXPAREL, which has completed Phase III clinical trials for postsurgical analgesia-nerve block administration.
The investigation is focused on allegations that the Company: (i) was overstating the efficacy of its EXPAREL drug; (ii) was improperly promoting its EXPAREL drug by claiming that it was be effective for up to 72 hours, when in fact, it is only approved for 24 hours of pain relief; (iii) improperly claimed that EXPAREL is safe for use in cholecystectomy and colectomy procedures, when approved labeling does not provide instructions for, or indicate that EXPAREL will be safe and effective for postsurgical pain, if used in such surgical procedures; and (iv) was deriving a substantial portion of its revenues from off-label marketing.
If you held Pacira shares since prior to April 9, 2012, and continue to hold your shares; and you are interested in discussing your rights or you have information relating to this investigation, please contact Roy L. Jacobs. Mr. Jacobs will be glad to personally speak with you at no cost to you.